STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #135 by analyst upside · 2026-06-27
ANVS
Annovis Bio, Inc.
Healthcare · Market Cap $73M · P/E 0x
ANALYST PRICE TARGET
+626.7%
implied upside to consensus target
Current Price $1.72
Consensus Target $12.5
Bull Target $17.0
Bear Target $8.0
Analysts Covering 2
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
1
Hold
0
Sell
0
52-Week Low $1.54
52-Week High $5.5
YTD Return -52.9%
FUNDAMENTALS
Market Cap $73M
P/E Ratio (TTM) N/A
Forward P/E -1.5x
EPS (TTM) $-1.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.54
52-Week High $5.5
Current Price $1.72
Bear Target $8.0
Bull Target $17.0
● Now $1.72 ● Target $12.5
TRADING DATA
Avg Volume 1.2M
YTD Return -52.9%
Analyst Count 2
Consensus Strong Buy
Upside to Target +626.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Annovis Bio, Inc. (ANVS) is currently trading at $1.72 with a Wall Street consensus price target of $12.5, implying potential upside of 626.7% over the next 12 months. 2 analysts currently cover ANVS, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $17.0, while the most cautious has a target of $8.0.

ANVS operates in the Healthcare sector with a market capitalisation of $73M. The stock is down 52.9% year-to-date and is currently trading near the lower end of its 52-week range of $1.54 – $5.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ANVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-04-14 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-09-30 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-09-03 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-06-09 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-05-15 Building track record
D. Boral Capital ↓ Downgrade
Buy → Hold 2025-02-10 32% win rate (25 calls)
D. Boral Capital — Reiterated
Buy → Buy 2024-11-11 32% win rate (25 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-11-11 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →